跳到正文
原文
STAT 主站· Jason Mast·· 3 天前AI 评分33

获1.73亿美元融资,Marrow Therapeutics瞄准镰状细胞病

STAT+: With $173 million, new startup takes aim at sickle cell

AI 导读

Marrow Therapeutics宣布成立并已筹集1.73亿美元A轮及B轮融资,投资方包括Scion Life Sciences、venBio和OrbiMed等。创始人Romesh Subramanian表示,该公司正开发一种用于治疗镰状细胞病的注射疗法,预期疗效与基因治疗相当但避免后者的诸多劣势,目前需进一步验证。

正文

Marrow Therapeutics is trying to build an injection as effective as gene therapy

A scanning electron micrograph of red blood cells in sickle cell anemia.Omikron/Science Photo Library

By Jason Mast

Nov. 17, 2026

General Assignment Reporter

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

For years, researchers and investors have been searching for a treatment that’s as effective in treating sickle cell disease as gene therapy — but without the many drawbacks. 

Biotech entrepreneur Romesh Subramanian thinks he might have one. On Tuesday, he announced the founding of new startup Marrow Therapeutics to pursue it, with $173 million in Series A and B funding from Scion Life Sciences, venBio, OrbiMed, and others.

“We expect it to be as good as [gene therapy] in patients,” Subramanian said, “but to be proven for sure.”

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. General Assignment Reporter

    Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

来源:STAT 主站 · statnews.com